Xcout IntelInternational Stem Cell CORP competitors & alternatives
The 12 closest competitors and alternatives to International Stem Cell CORP among biotech companies — ranked by similarity to what International Stem Cell CORP actually does, not by market-cap band.
Subscribe to see International Stem Cell CORP’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About International Stem Cell CORP
International Stem Cell Corporation (ISCO) is a clinical-stage biotechnology firm dedicated to creating therapeutic and biomedical solutions for a global market, spanning North America, Asia, Europe, and beyond. Central to its offerings are products derived from its proprietary human parthenogenetic stem cells, a unique form of pluripotent stem cells. ISCO is actively engaged in developing specialized cell types, such as neural stem cells, which hold promise for treating Parkinson's disease and other disorders affecting the central nervous system. Beyond therapeutics, the company also develops, manufactures, and commercializes anti-aging skincare products and an extensive range of human cell culture products. Its diverse portfolio of human cell culture products serves as vital research tools across numerous scientific disciplines. This includes specialized cells and reagents designed for studying: Dermatology: Skin diseases, toxicology, and wound healing. Cardiovascular & Oncology: Heart and blood vessel conditions, and various cancers. Respiratory: Bronchial and tracheal conditions, toxicity, cystic fibrosis, asthma, and pathogenesis. Reproductive & Urological: Prostate, renal, bladder, corneal, and female reproductive system diseases, as well as general cellular physiology. Musculoskeletal & Metabolic: Skeletal muscle biology, diabetes, insulin pathways, muscle repair, and myotube development. The company also provides adult stem cells for regenerative medicine research and a full complement of reagents and supplements essential for cell growth, staining, and cryopreservation. Distribution of ISCO's skincare range occurs via its website and specialized professional channels, while its human cell culture products reach customers through a dedicated sales force, original equipment manufacturer (OEM) partners, and authorized brand distributors. Established in 2001, International Stem Cell Corporation maintains its headquarters in San Diego, California.
International Stem Cell CORP at a glance
International Stem Cell CORP is a biotech company headquartered in San Diego, United States. It is publicly listed (ISCO) with a market capitalisation of $2.3M. Xcout tracks 8 named people at International Stem Cell CORP, including Andrey Semechkin (Co-Chairman of the Board & Chief Executive Officer).
International Stem Cell CORP leadership
- Andrey SemechkinCo-Chairman of the Board & Chief Executive Officer
- Rebecca McGeePresident of Lifeline Cell Technology
- Russell KernExecutive Vice President, Chief Scientific Officer, Principal Financial Officer & Director
- Andrey SemechkinDirector
- Charles J CasamentoDirector
- Paul V MaierDirector
2 more named people on record for International Stem Cell CORP, with roles, board committees and tenure — see the full roster →
Top 12 International Stem Cell CORP competitors
Ranked by semantic similarity — how close each company is to International Stem Cell CORP by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Biotechnology
iOrganBio is a biotechnology company founded in 2024 that develops AI-powered platforms for the precision engineering and manufacturing of human cells and organoids. The company's CellForge platform aims to create reproducible human cell models for research applications, including cardiac disease studies and biological simulation.
Similar biotech company
Maravai LifeSciences Holdings, Inc. is a life sciences company operating globally, supplying essential products that facilitate the advancement of drug therapies, diagnostics, innovative vaccines, and research into human diseases. Its diverse product line supports critical stages of biopharmaceutical development, featuring nucleic acids for both diagnostic and therapeutic applications, antibody-based solutions for detecting impurities in biopharmaceutical manufacturing, and tools for monitoring protein expression across different tissue types. The company conducts its operations through two distinct segments: Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment specializes in manufacturing and distributing products integral to gene therapy, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics. This encompasses reagents utilized in the chemical synthesis, modification, labeling, and purification of DNA and RNA. Additionally, this division provides messenger RNA, oligonucleotides, their foundational building blocks, plasmid DNA, and the proprietary CleanCap capping technology. Meanwhile, the Biologics Safety Testing segment offers analytical products vital for developing biologic manufacturing processes. Its offerings include bespoke antibody and assay development services tailored to specific products, alongside HCP ELISA kits, various other ELISA kits for identifying bioprocess impurities and contaminants, ancillary reagents, and custom service solutions. Maravai's clientele spans biopharmaceutical companies, other life sciences and biopharmaceutical research firms, academic research institutions, and in vitro diagnostics companies. Incorporated in 2020, Maravai LifeSciences Holdings, Inc. maintains its headquarters in San Diego, California.
Similar biotech company
CellSeed Inc. focuses on pioneering regenerative therapies that utilize cell sheet technology. The company is deeply involved in the research, development, and market introduction of advanced cell-sheet medicine products. Its innovations encompass epithelial cell sheets for repairing the esophagus, as well as both regenerated cartilage sheets and chondrocyte sheets aimed at addressing knee osteoarthritis. Beyond its therapeutic pipeline, CellSeed manufactures and distributes a range of specialized cell cultureware. This includes UpCell, a temperature-responsive cultureware vital for cell-sheet engineering; RepCell, another temperature-sensitive product designed for efficient cell collection; and HydroCell, distinguished by its low cell-binding properties. The firm also provides supporting equipment, such as ThermoPlate III, a heating element constructed from transparent glass, and cellZscope, an automated system for real-time cell monitoring. Additionally, CellSeed offers contract development and manufacturing services. Founded in 2001, the company's main operations are situated in Tokyo, Japan.
Biotechnology
AcroCyte Therapeutics, Inc. is a biotechnology company dedicated to overcoming common laboratory challenges through its proprietary R³CE rapid, reproducible, rare cell 3D expansion technology. Recognized with awards such as the Taiwan National Innovation Award, the company focuses on advancing biomedical research and cell-based applications.
Biotechnology
Bit Bio is a UK biotechnology company that develops technologies for precisely programming human cells, including its opti-ox platform for producing consistent, scalable cell types. It serves biomedical researchers, drug developers, and regenerative-medicine and cell-therapy developers with engineered human cells and related tools.
Similar biotech company
StemCyte is a global cord blood banking and regenerative therapeutics company that provides public and private umbilical cord blood and cord tissue preservation services for expectant families. The company processes, tests, and cryopreserves stem cells for family protection and clinical use, and supplies cellular materials for transplants and medical research.
Similar biotech company
Energenesis Biomedical CO.,LTD., a firm established in 2012 and headquartered in Taipei, Taiwan, is an active participant in the biomedicine sector. The company specializes in the development of a diverse range of medical solutions and research materials. Its primary pharmaceutical pipeline includes ENERGI-F703, which is currently undergoing Phase II clinical trials for the treatment of diabetic foot ulcers, and ENERGI-F701, a topical solution for addressing alopecia that is also in its second phase of clinical assessment. The comprehensive portfolio of therapeutic agents further encompasses: ENERGI-F711, formulated as a cream for burns. ENERGI-F702, designed to combat metabolic diseases. ENERGI-F704, targeting inflammatory bowel disease. ENERGI-F708, for the management of asthma. ENERGI-F705, aimed at controlling Parkinson's disease. ENERGI-F707, addressing mitochondrial deficiencies. ENERGI-F706, used to treat cachexia. ENERGI-F709, which serves as a vaccine adjuvant. ENERGI-F710, intended for the regulation of blood phosphate levels. Beyond its therapeutic developments, Energenesis Biomedical also provides a selection of scientific research products, including reagents for Western blotting, cell culture supplements, components for protein isolation and quantification, various laboratory dyes, and buffer solutions.
Biotechnology
Emerald Health Bioceuticals Inc. develops biology-based life science solutions focused on enhancing human, animal, and plant life. The company utilizes advanced research, fermentation, biomanufacturing, and process development to create safe and sustainable products for its partners and customers.
Biotechnology
International Bioceutical Co., LLC operates as a cannabinoid life sciences company that manufactures and supplies EU-GMP certified active pharmaceutical ingredients (APIs). The company serves pharmaceutical companies, nutraceutical brands, and animal health organizations worldwide by providing cannabinoid-based ingredients and product development support for human and veterinary use.
Similar biotech company
Yubo International Biotech Limited, operating through its various subsidiaries, primarily dedicates its efforts to the research, development, and practical application of endometrial stem cells. Beyond this core focus, the company also provides a diverse range of products, including solutions for respiratory health, skincare and hair care formulations, nutritious beverages, and personal care items tailored for both men and women. Furthermore, it delivers specialized stem cell services, such as cellular analysis and comprehensive health management consulting, all offered under the VIVCELL brand. The company's headquarters are located in Beijing, China.
Similar biotech company
An integrated regenerative medicine and longevity company focused on the research, manufacturing, and commercialization of regenerative health technologies, stem cell-derived products, wellness solutions, and advanced skincare.
Biotechnology
ImmuneBridge Inc. is a biotechnology company headquartered in San Francisco, California, that develops a hematopoietic stem cell (HSC) expansion and differentiation platform.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of International Stem Cell CORP and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for International Stem Cell CORPand every competitor above — in one live dashboard.
Subscribe to Xcout Intel →